Joseph Abner Zabner from 712 Mclean St, Iowa City, IA 52246, age 62, Phone: 319 337-9856

Dr. Joseph L Zabner, Iowa City IA - MD (Doctor of Medicine)

view source

Specialties:

Critical Care Medicine
Pulmonology

Address:

University Hosp/Clin Pulmnry Me
200 Hawkins Dr Suite C33Gh, Iowa City, IA 52242
319 384-5401 (Phone)

Certifications:

Critical Care Medicine, 1995
Internal Medicine, 2005
Pulmonary Disease, 1994

Awards:

Healthgrades Honor Roll

Languages:

English
Hebrew

Hospitals:

University Hosp/Clin Pulmnry Me
200 Hawkins Dr Suite C33Gh, Iowa City, IA 52242

University of Iowa Hospital and Clinics
200 Hawkins Drive, Iowa City, IA 52242

Education:

Medical School
University of Central Venezuela / Luis Razetti School of Medicine
Medical School
Dallas Co Hp Parkland Mem
Medical School
Presbyterian Hospital
Medical School
University Iowa Hosps and Clinics

Joseph L. Zabner

view source

Specialties:

Pulmonary Critical Care Medicine

Work:

University Of Iowa Hospital & Clinics Pulmonary Medicine
200 Hawkins Dr STE C33GH, Iowa City, IA 52242
319 356-1620 (phone), 319 353-6406 (fax)

Education:

Medical School
Univ Central De Venezuela, Esc De Med Luis Razetti, Caracas
Graduated: 1986

Conditions:

Abdominal Aortic Aneurysm
Acute Renal Failure
Anemia
Bacterial Pneumonia
Bronchial Asthma

Languages:

English
Spanish

Description:

Dr. Zabner graduated from the Univ Central De Venezuela, Esc De Med Luis Razetti, Caracas in 1986. He works in Iowa City, IA and specializes in Pulmonary Critical Care Medicine. Dr. Zabner is affiliated with University Of Iowa Hospitals & Clinics.

Joseph Lublin Zabner

view source

Specialties:

Internal Medicine
Critical Care Medicine
Pulmonary Disease

Education:

Universidad Central De Venezuela - Jose Maria Vargas (1987)

Us Patents

Aav5 Vector For Transducing Brain Cells And Lung Cells
view source
US Patent:

6855314, Feb 15, 2005
Filed:

Mar 22, 2000
Appl. No.:

09/533427
Inventors:

John A. Chiorini - Kensington MD, US
Robert M. Kotin - Bethesda MD, US
Beverly Davidson - North Liberty IA, US
Joseph Zabner - Iowa City IA, US
Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC
University of Iowa Research Foundation - Iowa City IA
International Classification:

A01N063/00
A01N065/00
A01N043/04
C12N015/63
C12N015/85
US Classification:

424 932, 424 931, 424 936, 4353201, 435455, 514 44
Abstract:

The present invention provides methods of delivering nucleic acids to specific regions, tissues and cell types of the CNS. More particularly the invention provides methods of delivering nucleic acids to cells of the CNS such as cerebellar cells and ependymal cells. The invention also provides methods of delivering nucleic acids to cells of the lung such as alveolar cells using AAV5 vectors and particles.

Cftr With A Partially Deleted R Domain And Uses Thereof
view source
US Patent:

7339046, Mar 4, 2008
Filed:

Feb 14, 2003
Appl. No.:

10/367507
Inventors:

Michael J. Welsh - Riverside IA, US
Lynda S. Ostedgaard - Iowa City IA, US
Joseph Zabner - Iowa City IA, US
Assignee:

University of Iowa Research Foundation - Iowa City IA
International Classification:

A61K 38/16
C07H 21/04
US Classification:

536 235, 530 231, 530 242, 435 691, 4353201, 4352523, 435325, 4352351
Abstract:

The present invention offers new therapies for treating Cystic Fibrosis (CF), that are based on novel DNA molecules and proteins encoded by the DNA molecules. The present invention features DNA molecules encoding CFTR having a partially deleted R domain. The partial deletions in the R domain are between residues 708 and 835 of the wild-type CFTR.

Use Of Xylitol To Reduce Ionic Strength And Activate Endogenous Antimicrobials For Prevention And Treatment Of Infections
view source
US Patent:

20020022668, Feb 21, 2002
Filed:

May 21, 2001
Appl. No.:

09/861841
Inventors:

Michael Welsh - Riverside IA, US
Joseph Zabner - Iowa City IA, US
International Classification:

A61K031/045
US Classification:

514/738000
Abstract:

A method for killing infectious microbial cells by exposing the microbial cells to endogenous antimicrobial compounds. Activation of the antimicrobials is achieved by addition of low permeability, non-ionic osmolytes to lower ionic strength in body fluids where the antimicrobials have been previously suppressed by alteration of ionic transport (increase in salt concentration). The method can be used to treat cystic fibrosis. Cystic fibrosis causes elevated salt concentrations in the airway surface liquid (ASL) occur due to the impaired chloride transport across the epithelia. Xylitol has been found to be an effective low permeability, non-ionic osmolyte for use in the present invention.

Use Of Xylitol To Reduce Ionic Strength And Activate Endogenous Antimicrobials For Prevention And Treatment Of Infections
view source
US Patent:

20040192786, Sep 30, 2004
Filed:

Jan 28, 2004
Appl. No.:

10/766506
Inventors:

Michael Welsh - Riverside IA, US
Joseph Zabner - Iowa City IA, US
Assignee:

UNIVERSITY OF IOWA RESEARCH FOUNDATION - Iowa City IA
International Classification:

A61K031/045
US Classification:

514/738000
Abstract:

A method for killing infectious microbial cells by exposing the microbial cells to endogenous antimicrobial compounds. Activation of the antimicrobials is achieved by addition of low permeability, non-ionic osmolytes to lower ionic strength in body fluids where the antimicrobials have been previously suppressed by alteration of ionic transport (increase in salt concentration). The method can be used to treat cystic fibrosis. Cystic fibrosis causes elevated salt concentrations in the airway surface liquid (ASL) occur due to the impaired chloride transport across the epithelia. Xylitol has been found to be an effective low permeability, non-ionic osmolyte for use in the present invention.

Use Of Xylitol To Reduce Ionic Strength And Activate Endogenous Antimicrobials For Prevention And Treatment Of Infections
view source
US Patent:

20060189701, Aug 24, 2006
Filed:

Apr 17, 2006
Appl. No.:

11/405345
Inventors:

Michael Welsh - Riverside IA, US
Joseph Zabner - Iowa City IA, US
Assignee:

UNIVERSITY OF IOWA RESEARCH FOUNDATION - Iowa City IA
International Classification:

A61K 31/045
US Classification:

514738000
Abstract:

A method for killing infectious microbial cells by exposing the microbial cells to endogenous antimicrobial compounds. Activation of the antimicrobials is achieved by addition of low permeability, non-ionic osmolytes to lower ionic strength in body fluids where the antimicrobials have been previously suppressed by alteration of ionic transport (increase in salt concentration). The method can be used to treat cystic fibrosis. Cystic fibrosis causes elevated salt concentrations in the airway surface liquid (ASL) occur due to the impaired chloride transport across the epithelia. Xylitol has been found to be an effective low permeability, non-ionic osmolyte for use in the present invention.

Cftr With A Partially Deleted R Domain And Uses Thereof
view source
US Patent:

20090227769, Sep 10, 2009
Filed:

Dec 7, 2007
Appl. No.:

11/999797
Inventors:

Michael J. Welsh - Riverside IA, US
Lynda S. Ostedgaard - Iowa City IA, US
Joseph Zabner - Iowa City IA, US
Assignee:

UNIVERSITY OF IOWA RESEARCH FOUNDATION - IOWA CITY IA
International Classification:

C07K 14/705
US Classification:

530350
Abstract:

The present invention offers new therapies for treating Cystic Fibrosis (CF), that are based on novel DNA molecules and proteins encoded by the DNA molecules. The present invention features DNA molecules encoding CFTR having a partially deleted R domain. The partial deletions in the R domain are between residues 708 and 835 of the wild-type CFTR.

Halides In The Treatment Of Pathogenic Infection
view source
US Patent:

20090246146, Oct 1, 2009
Filed:

Jan 9, 2009
Appl. No.:

12/351487
Inventors:

BOTOND BANFI - North Liberty IA, US
Anthony Fischer - Iowa City IA, US
Joseph Zabner - Iowa City IA, US
Lakshmi Durairaj - Iowa City IA, US
Daniel Lorentzen - North Liberty IA, US
International Classification:

A61K 9/12
A61K 33/16
A61K 33/18
A61K 33/00
A61P 11/00
US Classification:

424 43, 424667, 424673, 424600
Abstract:

The present invention relates to the use of halides and halide salts for the treatment of microbial infections, including those caused by bacteria, fungi and viruses. The present invention takes advantage of endogenous immune function and augments this system using a non-toxic and inexpensive reagent that can be delivered to mucosal surfaces, for example, orally, topically, opthalmically and via inhalation.

Method To Enhance Antimicrobial Activity By Increasing Ph
view source
US Patent:

20130316022, Nov 28, 2013
Filed:

Apr 26, 2013
Appl. No.:

13/871594
Inventors:

Joseph Zabner - Iowa City IA, US
Assignee:

University of Iowa Research Foundation - Iowa City IA
International Classification:

A61K 33/00
US Classification:

424715
Abstract:

The invention provides a method to enhance antimicrobial activity, e.g., in a mammal.